Parkinson's disease (PD) is a progressive neurodegenerative disorder related to the loss or absence of dopaminergic neurons in the brain. These deficits result in slowness of movement, tremor, rigidity, and dysfunction of behaviour. These symptoms negatively influence the patient’s capability to carry out the daily oral hygiene manoeuvres. The aim of this work is to record the oral health condition of PD patients evaluated at the IRCSS Bonino-Puleio in Messina. The oral health of 45 consecutive PD patients (study group) with neurologic diagnosis based on United Kingdom Brain Bank Criteria has been compared with that of another 45 no PD patients of the same age (control group). The evaluation of the general oral condition was recorded underlining tooth loss, active periodontal disease, and presence of untreated caries. The frequency of untreated caries, periodontal diseases, and missing teeth of the study group was significantly higher than in control group. Based on the data results, clinicians should direct high attention to the oral hygiene of patients with PD, above all at the early stages of the caries or periodontal disease, in order to prevent serious evolution of those pathologic dental conditions that may finally result in the tooth extraction event. 1. Introduction Parkinson’s disease (PD) is a progressive neurodegenerative disorder typically characterized by motor symptoms such as bradykinesia, rigidity, and postural instability with resting tremor. In addition, cognitive impairments are present, even in early disease stages, and predominantly affect executive functions such as planning abilities. Moreover, regarding a high risk for clinical dementia and clinical depression nondemented and nondepressed PD patients manifest themselves subtle cognitive problems, even in the earliest disease stages, which reflect incident pathological dementia and quality of life [1–6]. The motility impairment in PD patients is related with the damage and loss of about 60 to 70% of the neurons that memory and release dopamine in the substantia nigra. This disability results on the deletion of the neurotransmitter in the striatum area of the basal ganglia, basic to produce smooth and coordinated body movement [7–9]. Therefore, a large spectrum of no motor signs like hypotension, cardiac dysrhythmias, sweating bladder constipation, and sex dysfunction is typical of the PD Patients [10]. Parkinson tremors usually begin in a hand and then inducing alteration of the movements. Through the disease development, tremor involves the legs, face, tongue, and mandible [2,
References
[1]
I. Obeso, L. Wilkinson, E. Casabona et al., “Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson's disease,” Experimental Brain Research, vol. 212, no. 3, pp. 371–384, 2011.
[2]
R. G. Brown and C. D. Marsden, “How common is dementia in Parkinson's disease?” The Lancet, vol. 2, no. 8414, pp. 1262–1265, 1984.
[3]
C. W. Olanow and J. A. Obeso, “The significance of defining preclinical or prodromal Parkinson's disease,” Movement Disorders, vol. 27, no. 5, pp. 666–669, 2012.
[4]
R. Cools, “Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease,” Neuroscience & Biobehavioral Reviews, vol. 30, no. 1, pp. 1–23, 2006.
[5]
A. M. Owen, “Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry,” Neuroscientist, vol. 10, no. 6, pp. 525–537, 2004.
[6]
S. P. Woods and A. I. Tr？ster, “Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease,” Journal of the International Neuropsychological Society, vol. 9, no. 1, pp. 17–24, 2003.
[7]
P. Pollux, “Advance preparation of set-switches in Parkinson's disease,” Neuropsychologia, vol. 42, no. 7, pp. 912–919, 2004.
[8]
C. Frank, G. Pari, and J. P. Rossiter, “Approach to diagnosis of Parkinson disease,” Canadian Family Physician, vol. 52, no. 7, pp. 862–868, 2006.
[9]
V. Bhat and W. J. Weiner, “Parkinson's disease: diagnosis and the initiation of therapy,” Minerva Medica, vol. 96, no. 3, pp. 145–154, 2005.
[10]
D. S. Goldstein, B. A. Eldadah, C. Holmes et al., “Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment,” Hypertension, vol. 46, no. 6, pp. 1333–1339, 2005.
[11]
Y. Nakayama, M. Washio, and M. Mori, “Oral health conditions in patients with Parkinson's disease,” Journal of Epidemiology, vol. 14, no. 5, pp. 143–150, 2004.
[12]
J. Schwarz, E. Heimhilger, and A. Storch, “Increased periodontal pathology in Parkinson's disease,” Journal of Neurology, vol. 253, no. 5, pp. 608–611, 2006.
[13]
A. Barbeau, “Long term assessment of levodopa therapy in Parkinson's disease,” Canadian Medical Association Journal, vol. 112, no. 12, pp. 1379–1380, 1975.
[14]
C. D. Marsden and J. D. Parkes, “Success and problems of long term levodopa therapy in Parkinson's disease,” The Lancet, vol. 1, no. 8007, pp. 345–349, 1977.
[15]
J. A. Obeso, F. Grandas, J. Vaamonde et al., “Motor complications associated with chronic levodopa therapy in Parkinson's disease,” Neurology, vol. 39, no. 11, supplement 2, pp. 11–19, 1989.
[16]
M. R. Luquin, O. Scipioni, J. Vaamonde, O. Gershanik, and J. A. Obeso, “Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification,” Movement Disorders, vol. 7, no. 2, pp. 117–124, 1992.
[17]
O. Rascol, D. J. Brooks, A. D. Korczyn, P. P. De Deyn, C. E. Clarke, and A. E. Lang, “A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa,” The New England Journal of Medicine, vol. 342, no. 20, pp. 1484–1491, 2000.
[18]
S. Fukayo, K. Nonaka, T. Shimizu, and E. Yano, “Oral health of patients with Parkinson's disease: factors related to their better dental status,” Tohoku Journal of Experimental Medicine, vol. 201, no. 3, pp. 171–179, 2003.
[19]
Y. Shimazaki, I. Soh, T. Saito et al., “Influence of dentition status on physical disability, mental impairment, and mortality in institutionalized elderly people,” Journal of Dental Research, vol. 80, no. 1, pp. 340–345, 2001.
[20]
M. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, vol. 17, no. 5, pp. 427–442, 1967.
[21]
T. Wu, M. Trevisan, R. J. Genco, J. P. Dorn, K. L. Falkner, and C. T. Sempos, “Periodontal disease and risk of cerebrovascular disease: the first national health and nutrition examination survey and its follow-up study,” Archives of Internal Medicine, vol. 160, no. 18, pp. 2749–2755, 2000.
[22]
A. J. Grau, H. Becher, C. M. Ziegler et al., “Periodontal disease as a risk factor for ischemic stroke,” Stroke, vol. 35, no. 2, pp. 496–501, 2004.
[23]
T. Schillinger, W. Kluger, M. Exner et al., “Dental and periodontal status and risk for progression of carotid atherosclerosis: the inflammation and carotid artery risk for atherosclerosis study dental substudy,” Stroke, vol. 37, no. 9, pp. 2271–2276, 2006.
[24]
M. Persson, T. ？sterberg, A. K. Granérus, and S. Karlsson, “Influence of Parkinson's disease on oral health,” Acta Odontologica Scandinavica, vol. 50, no. 1, pp. 37–42, 1992.
[25]
D. L. Brunello and M. N. Mandikos, “Construction faults, age, gender, and relative medical health: factors associated with complaints in complete denture patients,” Journal of Prosthetic Dentistry, vol. 79, no. 5, pp. 545–554, 1998.
[26]
J. Silness and H. L？e, “Periodontal disease index,” Annals of Periodontology, vol. 4, pp. 655–669, 1964.
[27]
M. A. Botelho, J. G. Bezerra Filho, L. L. Correa, and J. Heukelbach, “Effect of a novel essential oil mouthrinse without alcohol on gingivitis: a double-blinded randomized controlled trial,” Journal of Applied Oral Science, vol. 15, no. 3, pp. 175–180, 2007.
[28]
P. D. Miller Jr., “A classification of marginal tissue recession,” The International Journal of Periodontics & Restorative Dentistry, vol. 5, no. 2, pp. 8–13, 1985.
[29]
C. Cheng, C. Graziani, and J. J. Diamond, “Cholesterol-lowering effect of the Food for Heart Nutrition Education Program,” Journal of the American Dietetic Association, vol. 104, no. 12, pp. 1868–1872, 2004.
[30]
B. Dawson-Hughes, S. S. Harris, E. A. Krall, and G. E. Dallal, “Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older,” The New England Journal of Medicine, vol. 337, no. 10, pp. 670–676, 1997.
[31]
C. Gazzotti, F. Arnaud-Battandier, M. Parello et al., “Prevention of malnutrition in older people during and after hospitalisation: results from a randomised controlled clinical trial,” Age and Ageing, vol. 32, no. 3, pp. 321–325, 2003.
[32]
H. M. Hudson, C. R. Daubert, and R. H. Mills, “The interdependency of protein-energy malnutrition, aging, and dysphagia,” Dysphagia, vol. 15, no. 1, pp. 31–38, 2000.
[33]
A. T. Merchant, W. Pitiphat, E. B. Rimm, and K. Joshipura, “Increased physical activity decreases periodontitis risk in men,” European Journal of Epidemiology, vol. 18, no. 9, pp. 891–898, 2003.
[34]
S. Fukayo, K. Nonaka, T. Shimizu, and E. Yano, “Oral health of patients with Parkinson's disease: factors related to their better dental status,” Tohoku Journal of Experimental Medicine, vol. 201, no. 3, pp. 171–179, 2003.
[35]
M. Shah, J. Deeb, M. Fernando et al., “Abnormality of taste and smell in Parkinson's disease,” Parkinsonism and Related Disorders, vol. 15, no. 3, pp. 232–237, 2009.
